



Published in final edited form as:

J Comb Chem. 2010 July 12; 12(4): 566–570. doi:10.1021/cc100054u.

Solid-Phase Synthesis of N-Substituted Pyrrolidinone Tethered N-substituted Piperidines *via* Ugi Reaction

Zhang Liu and Adel Nefzi

Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway, Port Saint Lucie, Florida 34987

Abstract

Starting with resin-bound glutamic acid, an efficient synthesis of N-substituted pyrrolidinones is described utilizing the Ugi four-component reaction (U-4CR). The same methodology is employed to produce N-substituted pyrrolidinone tethered N-substituted piperidines.

Solid-phase organic synthesis (SPOS) has emerged as a powerful approach for the rapid generation of structurally diverse compounds in the drug discovery community. One major focus of this field is the synthesis of bioactive compounds and their derivatives on the solid phase.¹ Multi-component reactions (MCRs) are one of the best tools in modern organic synthesis because of their productivity, simple procedures, convergence and facile execution.² One of the most important MCRs is the Ugi four-component reaction (U-4CR), in which a carboxylic acid, an amine, a carbonyl compound, and an isocyanide react in a one-step reaction, affording related compounds with variable structures.³ The Ugi four-component reaction is a powerful way to make library scaffolds containing a high number of substitution diversities. Therefore, it has been utilized very efficiently in conjugation with solid-phase organic synthesis to prepare large collections of molecules in a short reaction sequence.⁴

The N-substituted pyrrolidinone is an attractive drug template because of its extensive biological activities in various drug targets, such as Aspartic Protease,⁵ Beta-Amyloid Cleaving Enzyme (BACE),⁶ Progesterone Receptor (PR),⁷ Human Melanocortin-4 Receptor,⁸ Factor Xa,⁹ and HIV-1 Integrase.¹⁰ The development of new synthetic protocols for N-substituted pyrrolidinone derivatives are topics of continuous interest.¹¹ Herein, we would like to present our approach toward the solid-phase synthesis of enantiopure N-substituted pyrrolidinones, utilizing glutamic acid as a bifunctional reagent in an Ugi four-center three-component reaction (U-4C-3CR).¹² We also used the same methodology to create diversified N-substituted pyrrolidinone tethered N-substituted piperidines.

Polymer supported glutamic acid **2** was readily prepared by the coupling of L-Fmoc-Glu(^tBu)-OH to MBHA resin (Scheme 1). The generated resin bound bifunctional compound **2** was optimized for the solid phase Ugi reaction conditions. The initial attempt was carried out with benzyl isocyanide (1.1 equiv.) and cyclohexanone (1.1 equiv.) in acetonitrile/methanol (1:1) for 24 h at 65 °C. Following cleavage of the solid support, the desired product was obtained in 58% yield (Table 1, entry **4a**), with traces of starting material. In order to drive the reaction to completion, we used varying stoichiometries of the isocyanide and ketone. The better results were obtained using two fold excess of the reagents with a yield of 83% (Table 1, entry **4c**). We also tested the reaction under different

Supporting Information Available:

¹H-NMR and LC-MS of all the compounds. This information is available free of charge via the Internet at <http://pubs.acs.org/>.

reaction conditions by reducing the reaction time (Table 1, entry **4d**) or by lowering the temperature (Table 1, entry **4e**). In both cases, the reaction was incomplete and lower yields were obtained.

Under the optimized conditions (Table 1, entry **4c**), the scope of the solid phase Ugi reaction was explored using various isocyanides and ketones (Table 2). Polymer-supported glutamic acid was allowed to react with different isocyanides (2 equiv.) and ketones (2 equiv.) to afford the corresponding products in very good yields. We tried the same reaction conditions starting from resin-bound aspartic acid. The reaction was not successful and very low yields were obtained.

In order to increase the diversity, we used Boc-piperidone as the carbonyl reagent for the solid-phase Ugi reaction. Following the Ugi condensation of the resin-bound free glutamic acid **2** with isocyanide and Boc-piperidone, the Boc group was deprotected with 55% TFA/DCM and the resin-bound pyrrolidinone tethered piperidine **6** was treated with diversified capping agents such as sulfonyl chlorides, isocyanates, isothiocyanates and carboxylic acids (Scheme 2). In all cases, the reaction proceeded smoothly and the desired products **8** were obtained in high yields (Table 3).

In conclusion, we employed polymer supported glutamic acid as an efficient bifunctional component in Ugi reaction. Using this approach, we performed the parallel solid phase synthesis of enantiopure N-substituted pyrrolidinone derivatives tethered to different biologically relevant heterocycles such as piperidine.

Experimental Section

Procedure for the synthesis of polymer supported glutamic acid **2**

A 100 mg sample of *p*-methylbenzhydramine hydrochloride salt (MBHA) resin (1.15 mequiv/g, 100–200 mesh) was contained within a sealed polypropylene mesh packet.¹³ Reactions were carried out in polyethylene bottles. Following neutralization of the resin with 5% diisopropylethylamine (DIEA) in dichloromethane (DCM), L Fmoc-Glu(^tBu)-OH (6eq) was coupled using the conventional reagents hydroxybenzotriazole (HOBt, 6 equiv) and diisopropylcarbodiimide (DIC, 6 equiv.) in anhydrous DMF for 2 h. Completion of the coupling was monitored by the ninhydrin test.¹⁴ Following removal of *t*-Butyl group with 55% TFA/DCM and washing with DCM (3 ×), the Fmoc group was deprotected with 20% piperidine in DMF (2×10min). The resin was then washed with DMF (3×), ⁱPrOH (3×), DCM (3×).

General procedure for the solid-phase Ugi reaction: Synthesis of compounds **4** and **5**

Resin **2** was put in a solution of ketone (2 equiv.) in acetonitrile/methanol (4:1) for 1 h at 65 °C, and then isocyanide (2 equiv.) was added. After allowing the mixture to react at 65 °C for 24 h, the resin was washed with MeOH (3×), DMF (3×), DCM (3×) and dried. The completeness of the reaction was verified by cleavage and analysis with LC-MS. **4**: ¹H NMR (DMSO *d*₆): δ 1.30–1.86 (m, 10H, H on cyclohexane ring); 2.12–2.29 (m, 4H, H on pyrrolidine ring); 4.24 (m, 2H, H on benzyl group); 4.56 (m, 1H, H on pyrrolidine ring); 7.08–7.18 (m, 5H, H on benzyl group); 7.49 (s, 1H, H on amide group); 7.98 (s, 1H, H on amide group); 9.00 (t, 1H, *J* = 5.8 Hz, H on amide group). ¹³C NMR (DMSO *d*₆): δ 21.69 (C on piperidine ring), 22.12 (C on piperidine ring), 24.75 (C on pyrrolidine ring), 25.20 (C on piperidine ring), 29.64 (C on pyrrolidine ring), 31.00 (C on piperidine ring), 32.44 (C on piperidine ring), 42.18 (C on benzyl group), 58.24 (C on piperidine ring), 61.79 (C on pyrrolidine ring), 126.40 (C on benzyl group), 126.80 (2C, C on benzyl group), 128.03 (2C, C on benzyl group), 139.66 (C on benzyl group), 173.12 (C on amide group), 174.64 (C on amide group), 176.81 (C on amide group) ESI-MS: 343 (MH⁺).

5a: $^1\text{H NMR}$ (DMSO d_6): δ 1.71–1.89 (m, 4H, H on piperidine ring); 2.15–2.34 (m, 3H, H on piperidine ring); 2.76–2.89 (m, 2H, H on piperidine ring); 3.02–3.23 (m, 4H, m, 4H, H on pyrrolidine ring); 4.28 (m, 2H, H on benzyl group); 4.52 (m, 1H, H on pyrrolidine ring); 7.19–7.30 (m, 5H, H on benzyl group); 7.53 (s, 1H, H on amide group); 8.06 (s, 1H, H on amide group); 9.18 (t, 1H, $J = 5.7$ Hz, H on amide group)

ESI-MS: 345 (MH^+). **5b:** $^1\text{H NMR}$ (DMSO d_6): δ 1.11–1.86 (m, 20H, H on two piperidine rings); 2.08–2.28 (m, 4H, H on pyrrolidine ring); 3.48 (m, 1H, H on piperidine ring); 4.53 (m, 1H, H on pyrrolidine ring); 7.52 (s, 1H, H on amide group); 7.93 (s, 1H, H on amide group); 8.47 (m, 1H, H on amide group). ESI-MS: 336 (MH^+). **5c:** $^1\text{H NMR}$ (DMSO d_6): δ 0.84 (t, 3H, $J = 7.3$ Hz, H on the n-butyl group); 1.23–1.86 (m, 14H, H on the n-butyl group and cyclohexane ring); 2.09–2.28 (m, 4H, H on pyrrolidine ring); 2.99 (q, 2H, $J = 6.5$ Hz, H on the n-butyl group); 4.53 (m, 1H, H on pyrrolidine ring); 7.50 (s, 1H, H on amide group); 7.96 (s, 1H, H on amide group); 8.48 (m, 1H, H on amide group). ESI-MS: 310 (MH^+). **5d:** $^1\text{H NMR}$ (DMSO d_6): δ 1.28–1.86 (m, 10H, H on cyclohexane ring); 2.07–2.31 (m, 10H, H on 2-morpholinethyl group and pyrrolidine ring); 3.11 (m, 2H, H on 2-morpholinethyl group); 3.53 (t, 4H, $J = 4.6$ Hz, H on 2-morpholinethyl group); 4.51 (m, 1H, H on pyrrolidine ring); 7.44 (m, 1H, H on amide group); 7.92 (m, 1H, H on amide group); 8.47 (t, 1H, $J = 5.5$ Hz, H on amide group). ESI-MS: 367 (MH^+)

General procedure for the synthesis of compounds 8a-8c

Resin **5a** was shaken in 55% TFA/DCM for 30 min to remove the Boc group. Following neutralization with 5% DIEA/DCM, the resin was coupled with a carboxylic acid (6 equiv.) using conventional reagents HOBt (6 equiv.) and DIC (6 equiv.) in anhydrous DMF overnight. The resin was then washed with DMF (3 \times), DCM (3 \times), dried and cleaved with HF for 1.5 h at 0 $^\circ\text{C}$. All samples were purified by preparative HPLC and characterized by LC-MS and $^1\text{H-NMR}$. **8a:** $^1\text{H NMR}$ (DMSO d_6): δ 1.75–2.32 (m, 8H, H on piperidine ring); 3.46 (m, 4H, H on pyrrolidine ring); 4.28 (m, 2H, H on benzyl group); 4.57 (m, 1H, H on pyrrolidine ring); 7.20–7.28 (m, 5H, H on benzyl group); 7.37–7.39 (m, 2H, H on benzoyl group); 7.42–7.45 (m, 3H, H on benzoyl group); 7.53 (m, 1H, H on amide group); 7.96 (m, 1H, H on amide group); 9.11 (m, 1H, H on amide group). ESI-MS: 449 (MH^+). **8b:** $^1\text{H NMR}$ (DMSO d_6): δ 1.70–2.37 (m, 8H, H on piperidine ring); 3.40 (m, 4H, H on pyrrolidine ring); 3.67 (m, 2H, H on 2-phenylacetyl group); 4.26 (m, 2H, H on benzyl group); 4.48 (m, 1H, H on pyrrolidine ring); 7.19–7.23 (m, 6H, H on benzyl group and 2-phenylacetyl group); 7.26–7.32 (m, 4H, H on 2-phenylacetyl group); 7.52 (m, 1H, H on amide group); 7.95 (m, 1H, H on amide group); 9.12 (t, 1H, $J = 5.7$ Hz, H on amide group). ESI-MS: 463 (MH^+). **8c:** $^1\text{H NMR}$ (DMSO d_6): δ 1.58–2.31 (m, 25H, H on piperidine ring and adamaneacetyl group); 3.40 (m, 4H, H on pyrrolidine ring); 4.27 (m, 2H, H on benzyl group); 4.51 (m, 1H, H on pyrrolidine ring); 7.19–7.30 (m, 5H, H on benzyl group); 7.50 (m, 1H, H on amide group); 7.94 (s, 1H, H on amide group); 9.07–9.13 (m, 1H, H on amide group). ESI-MS: 521 (MH^+)

General procedure for the synthesis of compounds 8d-8i

Resin **5a** was shaken in 55% TFA/DCM for 30 min to remove the Boc group. Following neutralization with 5% DIEA/DCM, the resin was treated with DIEA (10 equiv.) and corresponding reagents, such as sulfonyl chloride, isocyanate or thioisocyanate (10 equiv.) in anhydrous DMF overnight. The resin was then washed with DMF (3 \times), DCM (3 \times), dried and cleaved by HF for 1.5 h at 0 $^\circ\text{C}$. All samples were purified by preparative HPLC and characterized. **8d:** $^1\text{H NMR}$ (DMSO d_6): δ 1.64–2.40 (m, 11H, H on piperidine ring and tosyl group); 3.41 (m, 4H, H on pyrrolidine ring); 4.15 (m, 2H, H on benzyl group); 4.49 (m, 1H, H on pyrrolidine ring); 7.13–7.26 (m, 5H, H on benzyl group); 7.44 (d, 2H, $J = 8.3$ Hz, H on tosyl group); 7.50 (s, 1H, H on amide group); 7.59 (d, 2H, $J = 8.3$ Hz, H on tosyl group);

7.94 (s, 1H, H on amide group); 8.98 (t, 1H, J= 5.7 Hz, H on amide group). ESI-MS: 499 (MH⁺). **8e**: ¹H NMR (DMSO *d*₆): δ 1.66–2.28 (m, 8H, H on piperidine ring); 3.49 (m, 4H, H on pyrrolidine ring); 4.09 (m, 2H, H on benzyl group); 4.49 (m, 1H, H on pyrrolidine ring); 7.07–7.20 (m, 5 H, H on benzyl group); 7.50 (s, 1H, H on amide group); 7.69–7.76 (m, 3H, H on naphthalene-2-ylsulfonyl); 7.94 (s, 1H, H on amide group); 8.08 (d, 1H, J= 8.0 Hz, H on naphthalene-2-ylsulfonyl); 8.17 (d, 1H J= 8.8 Hz, H on naphthalene-2-ylsulfonyl); 8.21 (d, 1H, J= 8.2 Hz, H on naphthalene-2-ylsulfonyl); 8.41 (s, 1H, H on naphthalene-2-ylsulfonyl); 8.95 (t, 1H, J= 5.6 Hz, H on amide group). ESI-MS: 535 (MH⁺). **8f**: ¹H NMR (DMSO *d*₆): δ 1.04 (d, 6H, J= 6.5, H on the isopropyl group); 1.58–2.37 (m, 8H, H on piperidine ring); 3.44 (m, 4H, H on pyrrolidine ring); 3.73 (m, 1H, H on the isopropyl group); 4.27 (m, 2H, H on benzyl group); 4.51 (m, 1H, H on pyrrolidine ring); 6.86 (s, 1H, H on urea); 7.19–7.30 (m, 5H, H on benzyl group); 7.52 (s, 1H, H on amide group); 7.96 (s, 1H, H on amide group); 9.09 (t, 1H, J= 5.7Hz, H on amide group). ESI-MS: 430 (MH⁺). **8g**: ¹H NMR (DMSO *d*₆): δ 1.24–2.34 (m, 8H, H on piperidine ring); 3.58 (m, 4H, H on pyrrolidine ring); 4.29 (m, 2H, H on benzyl group); 4.54 (m, 1H, H on pyrrolidine ring); 7.20–7.30 (m, 7H, H on benzyl group and phenyl group); 7.44 (m, 2H, H on phenyl group); 7.53 (s, 1H, H on amide group); 7.96 (s, 1H, H on amide group); 8.47 (s, 1H, H on urea); 9.13 (t, 1H, J= 5.8 Hz, H on amide group). ESI-MS: 464 (MH⁺). **8h**: ¹H NMR (DMSO *d*₆): δ 1.08 (t, 3H, J= 7.2 Hz, H on ethyl group); 1.23–2.38 (m, 8H, H on piperidine ring); 3.41–3.48 (m, 6H, H on pyrrolidine ring and ethyl group); 4.28 (m, 2H, H on benzyl group); 4.50 (m, 1H, H on pyrrolidine ring); 6.87 (s, 1H, H on thiourea); 7.19–7.30 (m, 5H, H on benzyl group); 7.54 (s, 1H, H on amide group); 7.97 (s, 1H, H on amide group); 9.15 (t, 1H, J= 5.7 Hz, H on amide group). ESI-MS: 432 (MH⁺). **8i**: ¹H NMR (DMSO *d*₆): δ 1.23–2.38 (m, 8H, H on piperidine ring); 3.50–3.89 (m, 4H, H on pyrrolidine ring); 4.30 (m, 2H, H on benzyl group); 4.56 (m, 1H, H on pyrrolidine ring); 7.09 (m, 1H, H on benzyl group); 7.28 (m, 9H, H on benzyl group and phenyl group); 7.56 (s, 1H, H on amide group); 8.00 (s, 1H, H on amide group); 9.19 (t, 1H, J= 5.7 Hz, H on amide group); 9.28 (s, 1H, H on thiourea). ESI-MS: 480 (MH⁺).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


Acknowledgments

The authors would like to thank the State of Florida Funding, NIH (1R03DA025850-01A1, Nefzi), NIH (5P41GM081261-03, Houghten) and NIH (3P41GM079590-03S1, Houghten) for their financial support.


References and Notes

- (a) Ziegert RE, Toräng J, Knepper K, Bräse S. *J Comb Chem.* 2005; 7:147–169. [PubMed: 15762741] (b) Kundu B. *Curr Opin Drug Discovery Dev.* 2003; 6:815–826. (c) Feliu L, Vera-Luque P, Albericio F, Alvarez M. *J Comb Chem.* 2007; 9:521–565. [PubMed: 17497931] (d) Gil C, Bräse S. *J Comb Chem.* 2009; 11:175–197. [PubMed: 19053506]
- (a) Zhu, J.; Bienaymé, H., editors. *Multicomponent Reactions.* Wiley-VCH; Weinheim: 2005. and references therein (b) Simila STM, Martin SF. *Tet Lett.* 2008; 49:450. (c) El Kaim L, Grimaud L. *Tetrahedron.* 2009; 65:2153. (d) Hulme C, Dietrich J. *Molecular Diversity.* 2009; 13:195. [PubMed: 19205916] (e) Domling A. *Chem Rev.* 2006; 106:17. [PubMed: 16402771]
- (a) Dömling A. *Chem Rev.* 2006; 106:17–89. [PubMed: 16402771] (b) Marcaccini S, Torroba T. *Nat Protoc.* 2007; 2:632–639. [PubMed: 17406624] (c) Dömling A, Ugi I. *Angew Chem, Int Ed.* 2000; 39:3168–3210. (d) Ugi I, Werner B, Dömling A. *Molecules.* 2003; 8:53–56. (e) Main M, Snaith JS, Meloni MM, Jauregui M, Sykes D, Faulkner S, Kenwright AM. *Chem Commun.* 2008:5212–5214.

4. (a) Pulici M, Quartieri F, Felder ER. *J Comb Chem*. 2005; 7:463–473. [PubMed: 15877475] (b) Hoel AML, Nielson J. *Tetrahedron Lett*. 1999; 40:3941–3944. (c) Tempest RA, Brown SD, Armstrong RW. *Angewandte Chemie, International Edition in English*. 1996; 35:640. (d) Lin Q, O'Neill JC, Blackwell HE. *Organic Letters*. 2005; 7:4455. [PubMed: 16178557] (e) Stocker, AM.; Keating, TA.; Tempest, PA.; Armstrong, RW. *Tetrahedron Letters*. 1996. p. 1149 (f) Golebiowski A, Jozwik J, Klopfenstein SR, Colson A-O, Grieb AL, Russell AF, Rastogi VL, Diven CF, Portlock DE, Chen JJ. *Journal of Combinatorial Chemistry*. 2002; 4:584. [PubMed: 12425603] (g) Golebiowski A, Jozwik J, Klopfenstein SR, Colson A-O, Grieb AL, Russell AF, Rastogi VL, Diven CF, Portlock DE, Chen JJ. *Journal of Combinatorial Chemistry*. 2002; 4:584–590. [PubMed: 12425603] (e) Suda A, Ohta A, Sudoh M, Tsukuda T, Shimma N. *Heterocycles*. 2001; 55:1023. (f) Sutherlin DP, Stark TM, Hughes R, Armstrong RW. *Journal of Organic Chemistry*. 1996; 61:8350. [PubMed: 11667836] (h) Stocker AM, Keating TA, Tempest PA, Armstrong RW. *Tetrahedron Letters*. 1996; 37:1149.
5. Hanessian S, Yun H, Hou Y, Tintelnot-Blomley M. *J Org Chem*. 2005; 70:6746–6756. [PubMed: 16095294]
6. Iserloh U, Pan J, Stamford AW, Kennedy ME, Zhang Q, Zhang L, Parker EM, McHugh NA, Favreau L, Strickland C, Voit J. *Bioorg Med Chem Lett*. 2008; 18:418–422. [PubMed: 17980584]
7. Washburn DG, Hoang TH, Frazee JS, Johnson L, Hammond M, Manns S, Madauss KP, Williams SP, Duraiswami C, Tran TB, Stewart EL, Grygielko ET, Glace LE, Trizna W, Nagilla R, Bray JD, Thompson SK. *Bioorg Med Chem Lett*. 2009; 19:4664–4668. [PubMed: 19616429]
8. Jiang W, Tucci FC, Tran JA, Fleck BA, Wen J, Markison S, Marinkovic D, Chen CW, Arellano M, Hoare SR, Johns M, Foster AC, Saunders J, Chen C. *Bioorg Med Chem Lett*. 2007; 17:5610–5613. [PubMed: 17822895]
9. (a) Gong Y, Becker M, Choi-Sledeski YM, Davis RS, Salvono JM, Chu V, Brown KD, Pauls HW. *Bioorg Med Chem Lett*. 2000; 10:1033–1036. [PubMed: 10843210] (b) Choi-Sledeski YM, McGarry DG, Green DM, Mason HJ, Becker MR, Davis RS, Ewing WR, Dankulich WP, manetta VE, Morris RL, Spada AP, Cheney DL, Brown KD, Colussi DJ, Chu V, Heran CL, Morgan SR, Bentley RG, Leadley RJ, Maigan S, Guilloteau JP, Dunwiddie CT, Pauls HW. *J Med Chem*. 1999; 42:3572–3587. [PubMed: 10479289]
10. Melamed JY, Egbertson MS, Varga S, Vacca JP, Moyer G, Gabryelski L, Felock PJ, Stillmock KA, Witmer MV, Schleif W, Hazuda DJ, Leonard Y, Jin L, Ellis JD, young SD. *Bioorg Med Chem Lett*. 2008; 18:5307–5310. [PubMed: 18774711]
11. (a) Pelletier SMC, Ray PC, Dixon DJ. *Org Lett*. 2009; 11:4512–4515. [PubMed: 19764710] (b) Donohoe TJ, Chiu JYK, Thomas RE. *Org Lett*. 2007; 9:421–424. [PubMed: 17249777] (c) Tellitu I, Serna S, Herrero MT, Moreno I, Dominguez E, SanMartin R. *J Org Chem*. 2007; 72:1526–1529. [PubMed: 17288399] (d) Medina JR, Blackledge CW, Erhard KF, Axten JM, Miller WH. *J Org Chem*. 2008; 73:3946–3949. [PubMed: 18429635] (e) Wardrop DJ, Burge MS. *J Org Chem*. 2005; 70:10271–10284. [PubMed: 16323835]
12. Gedey S, Van der Eychen J, Fulop F. *Org Lett*. 2002; 4:1967–1969. [PubMed: 12027659]
13. Houghten RA. *Proc Natl Acad Sci USA*. 1985; 82:5131. [PubMed: 2410914]
14. Kaiser E, Colescott RL, Bossinger CD, Cook PI. *Analytical Biochemistry*. 1970; 34:595. [PubMed: 5443684]

**Scheme 1.**

Reagents and conditions: (a) 55% TFA/DCM, 1h; (b) 20% piperidine/DMF, 10 min, twice; (c) Benzyl isocyanide/Cyclohexanone (1:1) in Acetonitrile/MeOH (4:1); (d) HF/anisole, 1.5 h, 0 °C.

**Scheme 2.**

Reagents and conditions: (a) Benzyl isocyanide, N-Boc-4-piperidinone, acetonitrile/methanol (4:1), 65 °C, 24 h; (b) 55% TFA/DCM; (c) Acid, DIC, HOBT, DMF, r.t., overnight or Sulfonyl chloride/isocyanate/thioisocyanate, DIEA, DMF, r.t., overnight; (d) HF cleavage, 0 °C, 1.5 h.

Table 1
Screening of reaction conditions for the solid-phase Ugi multi-component reaction

| Entry | Reagents (equiv.) | | | time (h) | Temp (°C) | yield (%) ^a |
|-----------|-------------------|------|---------------|----------|-----------|------------------------|
| | PS Glu | BnNC | Cyclohexanone | | | |
| 4a | 1 | 1.1 | 1.1 | 24 | 65 | 58 |
| 4b | 1 | 1.5 | 1.5 | 24 | 65 | 75 |
| 4c | 1 | 2 | 2 | 24 | 65 | 83 |
| 4d | 1 | 2 | 2 | 12 | 65 | 66 |
| 4e | 1 | 2 | 2 | 24 | 25 | 51 |

^aYields based on the weight of purified product and are relative to the initial loading of the resin. The purity of the purified compounds is higher than 95% for all the compounds. The purity was estimated on analytical traces at $\lambda=214$ nm and 254 nm.

Table 2










Synthesis of substituted pyrrolidinones.

| Entry | R ₁ | Y | X | Obtained MW | Yield (%) ^a |
|-------|----------------|--------------------|--------------------|------------------------|------------------------|
| 5a | | -NBoc- | -NH- | 345 (MH ⁺) | 80 |
| 5b | | -CH ₂ - | -CH ₂ - | 336 (MH ⁺) | 82 |
| 5c | | -CH ₂ - | -CH ₂ - | 310 (MH ⁺) | 78 |
| 5d | | -CH ₂ - | -CH ₂ - | 367 (MH ⁺) | 70 |

^aYields based on the weight of purified product and are relative to the initial loading of the resin. The purity of the purified compounds is higher than 95% for all the compounds. The purity was estimated on analytical traces at $\lambda=214$ nm and 254 nm.

Table 3

Substituted piperidine products obtained

| Entry | R | Obtained MW | Yield (%) ^a |
|-------|---|------------------------|------------------------|
| 8a |  | 449 (MH ⁺) | 76 |
| 8b |  | 463 (MH ⁺) | 72 |
| 8c |  | 521 (MH ⁺) | 68 |
| 8d |  | 499 (MH ⁺) | 82 |
| 8e |  | 535 (MH ⁺) | 85 |
| 8f |  | 430 (MH ⁺) | 74 |
| 8g |  | 464 (MH ⁺) | 79 |
| 8h |  | 432 (MH ⁺) | 72 |
| 8i |  | 480 (MH ⁺) | 80 |

^aYields based on the weight of purified product and are relative to the initial loading of the resin. The purity of the purified compounds is higher than 95% for all the compounds. The purity was estimated on analytical traces at $\lambda = 214$ nm and 254 nm.